LOUISVILLE, Ky. -- June 16, 2026, June 16, 2026 (GLOBE NEWSWIRE) --
Chronic pain is shaping how millions of Americans live, move, sleep, work, and recover. New findings from Confluent Health suggest the healthcare system may still be falling short in addressing it.
Today, Confluent Health officially launched The Pain Perspective, a groundbreaking new report capturing insights from more than 1,300 patients, musculoskeletal (MSK) clinicians, and referring physicians across the United States. The report offers one of the most comprehensive looks to date at how people experience chronic musculoskeletal (MSK) pain, the barriers preventing access to effective care, and what patients say they actually want from treatment.
And the message is clear: patients are looking for more than temporary relief. They want care that restores movement, improves quality of life, and treats the whole person.
Among the report’s key findings:
85% of patients surveyed report living with chronic pain lasting longer than one yearMore than 80% say pain limits their daily activities65% report mental health challenges related to their painNearly half avoided seeking care because of cost9 in 10 would recommend physical therapy The findings also reveal growing demand for conservative, non-pharmacologic care approaches focused on movement, education, and long-term recovery rather than symptom management alone.
“Pain is not just physical, and patients are telling us that loudly and clearly,” said Dr. Kristi Henderson, CEO of Confluent Health. “What we’re seeing in this report is a growing disconnect between what patients need and what traditional pain care pathways have historically delivered. There is an enormous opportunity to rethink how care is designed, delivered, and experienced.”
Patients surveyed overwhelmingly emphasized the importance of whole-person care, with 87% saying it is important for providers to address both physical and mental health as part of recovery. The report also found strong alignment among clinicians and referring physicians around movement-based treatment models and PT-first care pathways.
For Confluent Health, The Pain Perspective is more than a report release. It’s the foundation of a broader movement to reshape how chronic pain is understood, discussed, and treated across the healthcare industry. Throughout 2026, the report will serve as the cornerstone of Confluent Health’s ongoing campaign exploring the realities of chronic pain through educational resources, executive thought leadership, patient storytelling, and “Pain, Misunderstood,” the organization’s powerful documentary examining the lived experiences behind the data.
“At Confluent Health, we believe movement is medicine,” said Henderson. “Patients deserve care that helps them regain confidence, function, and hope. Not just temporarily manage symptoms.”
The full report is available now at confluenthealth.com/pain-perspective.
###
About Confluent Health
Confluent Health, a nationwide network of physical and occupational therapy companies, is at the forefront of advancing musculoskeletal solutions that make us all stronger. We deliver better patient outcomes, reduce costs of care, improve workplace wellness, provide best-in-class education services, help prevent injuries, and play a crucial role in shaping industry best practices. For more information, visit confluenthealth.com or find us on LinkedIn.
Blair William and Co. IL trimmed its holdings in shares of Confluent, Inc. (NASDAQ: CFLT) by 10.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 144,126 shares of the company's stock after selling 16,449 shares during the quarter. Blair William
Aurora Mobile (NASDAQ: JG - Get Free Report) and Confluent (NASDAQ: CFLT - Get Free Report) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Analyst Ratings This is a summary of
Alight Capital Management LP acquired a new stake in Confluent, Inc. (NASDAQ: CFLT) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company's stock, valued at approximately $3,960,000. Alight Capital Management LP owned approximately 0.06%
Bamco Inc. NY lowered its holdings in Confluent, Inc. (NASDAQ: CFLT) by 60.6% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 65,000 shares of the company's stock after selling 100,000 shares during the quarter. Bamco Inc. NY's holdings in Confluent were worth
IBM CEO Arvind Krishna discusses the company's completion of its $11 billion acquisition of Confluent. Speaking with Caroline Hyde on "Bloomberg Open Interest," Krishna also says AI is a tailwind for the company and hasn't resulted in a net decrease in workers.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. ("Confluent" or the "Company") (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Confluent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Confluent reported its financial results for the second quarter of 2025. Among other items, Confluent disclosed that "an AI-native customer has been making a broad-based move towards self-management of internal data platforms." Confluent advised that this shift resulted in reduced usage of Confluent Cloud, and while the Company secured a Confluent Platform deal with the client in Q3 to continue supporting their streaming needs, the transition "represents a significant reduction in total spending with Confluent starting in Q4." Consequently, the change is "expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits."
On this news, Confluent's stock price fell $8.67 per share, or 32.86%, to close at $17.73 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Confluent, Inc. (NASDAQ: CFLT - Get Free Report) has been assigned an average rating of "Hold" from the thirty-three brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, twenty-eight have issued a hold recommendation, three have assigned a buy recommendation and one has assigned a
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. (“Confluent” or the “Company”) (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Confluent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Confluent reported its financial results for the second quarter of 2025. Among other items, Confluent disclosed that “an AI-native customer has been making a broad-based move towards self-management of internal data platforms.” Confluent advised that this shift resulted in reduced usage of Confluent Cloud, and while the Company secured a Confluent Platform deal with the client in Q3 to continue supporting their streaming needs, the transition “represents a significant reduction in total spending with Confluent starting in Q4.” Consequently, the change is “expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits.”
On this news, Confluent’s stock price fell $8.67 per share, or 32.86%, to close at $17.73 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. ("Confluent" or the "Company") (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Confluent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Confluent reported its financial results for the second quarter of 2025. Among other items, Confluent disclosed that "an AI-native customer has been making a broad-based move towards self-management of internal data platforms." Confluent advised that this shift resulted in reduced usage of Confluent Cloud, and while the Company secured a Confluent Platform deal with the client in Q3 to continue supporting their streaming needs, the transition "represents a significant reduction in total spending with Confluent starting in Q4." Consequently, the change is "expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits."
On this news, Confluent's stock price fell $8.67 per share, or 32.86%, to close at $17.73 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. (“Confluent” or the “Company”) (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Confluent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Confluent reported its financial results for the second quarter of 2025. Among other items, Confluent disclosed that “an AI-native customer has been making a broad-based move towards self-management of internal data platforms.” Confluent advised that this shift resulted in reduced usage of Confluent Cloud, and while the Company secured a Confluent Platform deal with the client in Q3 to continue supporting their streaming needs, the transition “represents a significant reduction in total spending with Confluent starting in Q4.” Consequently, the change is “expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits.”
On this news, Confluent’s stock price fell $8.67 per share, or 32.86%, to close at $17.73 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. ("Confluent" or the "Company") (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Capricorn Fund Managers Ltd purchased a new position in shares of Confluent, Inc. (NASDAQ: CFLT) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 130,391 shares of the company's stock, valued at approximately $3,943,000. A number of other institutional investors have also modified
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. (“Confluent” or the “Company”) (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
International Business Machines Corp (NYSE:IBM) is expected to report first-quarter results largely in line with forecasts on April 22, but Bank of America is adjusting estimates following the earlier-than-expected closing of its Confluent acquisition The bank said it anticipates an “inline quarter,” with recently acquired Confluent contributing roughly $50 million in revenue during the period after the deal closed on March 17, about one quarter earlier than previously assumed. Bank of America said IBM is likely to keep its full-year 2026 guidance unchanged, as management is expected to offset near-term dilution from the acquisition with a combination of additional revenue contribution and cost synergies.
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. (“Confluent” or the “Company”) (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. ("Confluent" or the "Company") (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Confluent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 30, 2025, Confluent reported its financial results for the second quarter of 2025. Among other items, Confluent disclosed that "an AI-native customer has been making a broad-based move towards self-management of internal data platforms." Confluent advised that this shift resulted in reduced usage of Confluent Cloud, and while the Company secured a Confluent Platform deal with the client in Q3 to continue supporting their streaming needs, the transition "represents a significant reduction in total spending with Confluent starting in Q4." Consequently, the change is "expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits."
On this news, Confluent's stock price fell $8.67 per share, or 32.86%, to close at $17.73 per share on July 31, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Confluent, Inc. (“Confluent” or the “Company”) (NASDAQ: CFLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
May 01, 2026 12:30 ET | Source: Confluent Medical Technologies
SCOTTSDALE, Ariz., May 01, 2026 (GLOBE NEWSWIRE) -- Confluent Medical Technologies, Inc. (“Confluent”), a leading medical device and materials science contract manufacturer specializing in Nitinol and polymer components, today announced that Tom Testa, has been appointed as Chief Operating Officer ("COO") for the company, effective April 29th, 2026.
"We are thrilled to welcome Tom to Confluent," said Dean Schauer, Confluent’s President, CEO, and Chairman. "Tom has exceptional experience in all aspects of Executive Leadership in the Medical Device Manufacturing and Development space as well as leadership across multiple, successful, MedTech organizations. As Confluent continues its significant growth, the addition of Tom to our company will further enhance the strength of our industry-leading team."
As COO, Mr. Testa’s responsibilities will span global operations, and he will oversee Confluent’s operations, supply chain, global product development, and environmental health & safety.
Mr. Testa joins Confluent from Corza Medical where he served as CEO and CFO. Prio to that, Tom served as Vice President & General Manager of the Nordson Medical business which he joined following the acquisition of the Vention Medical Advanced Technologies Business where he served as President. Tom holds a Bachelor of Science degree in Chemical Engineering from New Jersey Institute of Technology as well as an MBA in Finance from New York University.
Commenting on his appointment, Mr. Testa said: “I’m excited to join Confluent at such a pivotal moment in its growth. The company has built a strong reputation as a trusted partner to leading medical device innovators, grounded in its differentiated materials science expertise and vertically integrated manufacturing capabilities. I look forward to working with this talented team to further strengthen operational excellence, expand our global footprint, and help drive the next phase of sustainable growth for our customers and the patients they serve.”
About Confluent Medical Technologies, Inc.:
Confluent Applies Materials Science to MedTech Innovation. Confluent specializes in the expert design, development, and large-scale manufacturing of interventional catheter-based devices and implants. Customers rely on Confluent’s expertise in Nitinol material and components, balloon and complex catheters, high-precision polymer tubing, and implantable textiles. With facilities in Fremont and Orange County, California; Warwick, Rhode Island; Windham, Maine; Austin, Texas; Chattanooga, Tennessee; San Jose, Costa Rica; and Hyderabad, India, Confluent has earned the confidence of the leaders in the medical device community through a proven track record of innovative materials science, engineering, and manufacturing. For more information, visit confluentmedical.com.
LONDON--(BUSINESS WIRE)--Confluent, an IBM Company and the data streaming pioneer, today announced new capabilities in Confluent Intelligence and Confluent Cloud that streamline how real-time artificial intelligence (AI) applications are built and secured. These updates remove the security and complexity barriers that stop organizations from moving AI workloads into the real world: Confluent unifies the AI life cycle with tools that developers already live in, integrating Apache Flink® pipeline.
